Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Inclusion criteria

• Willing to sign the informed consent, and willing to attend follow-up visits.
• Age ≥ 50
• Diagnosis of active CNV secondary to neovascular AMD
• BCVA ETDRS letters between 5 and 63
• Subjects must have received a minimum of 2 injections within 6 months prior to screening and demonstrated a meaningful response to anti-VEGF therapy
• Male subjects whose partner is a fertile female or female subjects who are fertile, agree to take effective contraceptive measures from the screening period until the last follow-up.

Exclusion criteria

• CNV or macular edema in the study eye secondary to diseases other than nAMD
• Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or any condition preventing visual acuity improvement
• Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, TIA in the last 6 months
• Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg
• Uncontrolled diabetes defined as HbA1c >8.0% within 28 days prior to screening